Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Core Insights - Kiniksa Pharmaceuticals reported a preliminary unaudited net product revenue of $416.4 million for ARCALYST in 2024, reflecting approximately 79$560 million and $580 million [1][6] - Kiniksa expects to maintain a cash flow positive status on an annual basis [1][6] Commercial Performance - As of the end of 2024, around 13% of the target population for recurrent pericarditis was on ARCALYST therapy, contributing to the revenue growth [2][6] - Since the launch of ARCALYST, over 2,850 prescribers have written prescriptions for the drug [6] - The average duration of ARCALYST therapy in recurrent pericarditis patients was approximately 27 months by the end of Q4 2024 [6] Corporate Update - Kiniksa's leadership, including Chairman and CEO Sanj K. Patel, presented at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [4] - The company is focused on advancing its clinical portfolio to address unmet medical needs [2][5] Product Information - ARCALYST is a recombinant dimeric fusion protein that inhibits interleukin-1 alpha and beta signaling, approved for treating recurrent pericarditis and other conditions [6][7] - The drug received Orphan Drug Exclusivity from the FDA for recurrent pericarditis in 2021 and Orphan Drug Designation from the European Commission for idiopathic pericarditis [7]